| MYGN Snapshot | |
|---|---|
| Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah. | |
| VALUATION DATA | |
| Market Capitalization | $1,674,753,000 | Price to Sales | 5.00 |
| Earnings per Share | $-3.1800 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $18.5000 |
| 52 Week High | $2.333 |
| 52 Week Low | $2.243 |
| 50-Day Moving Average | $2.348 |
| 200-Day Moving Average | $-8.96 |
| All data are from Alpha Vantage as of today. For more infomation on MYGN see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search